Pilot evaluation of safety, efficacy, and tolerability of a new topical formulation for facial hyperpigmentation, combining ascorbyl tetraisopalmitate and crosslinked resilient hyaluronic acid

This study evaluated therapy of facial hyperpigmentation with a novel topical formulation combining two synergistic melanogenesis inhibitors: ascorbyl tetraisopalmitate (ATIP), the esterified form of vitamin C (concentration equivalent to 8% L-ascorbic acid), and crosslinked resilient hyaluronic acid (RHA). Vitamin C inhibits multiple oxidative steps during melanogenesis, diminishing tyrosinase activity. Clinical challenges with L-ascorbic acid include low skin penetrance, instability due to oxidation, and potential irritation.